NAPLEX (North American Pharmacist Licensure Examination) Practice Exam

Disable ads (and more) with a membership for a one time $4.99 payment

Ace your North American Pharmacist Licensure Examination (NAPLEX) with our comprehensive practice test. Features include interactive flashcards, multiple-choice questions, with detailed hints and explanations. Fast-track your pharmacy career today!

Start Multiple Choice Practice Test
Start Flash Cards

Practice this question and more.

Which JAK inhibitor is mentioned first?

  1. Baracitinib (Olumiant)

  2. Upadacitinib (Rinvoq)

  3. Tofacitinib (Xeljanz)

  4. None of the above

The correct answer is: Tofacitinib (Xeljanz)

Tofacitinib (Xeljanz) is the JAK inhibitor mentioned first among the options provided. Tofacitinib was the first JAK inhibitor approved by the FDA for the treatment of rheumatoid arthritis, followed by the approvals of Baricitinib (Olumiant) and Upadacitinib (Rinvoq). Therefore, the correct answer is C.

More Questions Like This